1. Home
  2. Stocks
  3. Ajantpharm Share Price
  • Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Ajanta Pharma Share Price

    Large Cap
    ₹3,350.35
    + 20.25 (0.61%)
    08 September, 2024 07:16 BSE: 532331 NSE: AJANTPHARM ISIN: INE031B01049
    Bonus

    Start SIP in Ajanta Pharma

    Start SIP

    Ajanta Pharma Performance

    Day Range

    • Low 3,292
    • High 3,409
    ₹ 3,350

    52 Week Range

    • Low 1,650
    • High 3,409
    ₹ 3,350
    • Open Price3,345
    • Previous Close3,330
    • Volume255583

    Ajanta Pharma Chart

    • Over 1 Month + 13.97%
    • Over 3 Month + 38.4%
    • Over 6 Month + 60.22%
    • Over 1 Year + 90.15%

    Ajanta Pharma Key Statistics

    P/E Ratio 49
    PEG Ratio 1.3
    Market Cap Cr
    Price to Book Ratio 11.8
    EPS 63.7
    Dividend 0.8
    Relative Strength Index 71.89
    Money Flow Index 84.01
    MACD Signal 153.47
    Average True Range 127.03

    Ajanta Pharma Investment Rating

    • Master Rating:

    • Ajanta Pharma has an operating revenue of Rs. 4,332.59 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 26% is great, ROE of 22% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 24% and 44% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 31% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 82 which is a GOOD score indicating consistency in earnings, a RS Rating of 80 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 52 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Ajanta Pharma Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,0779261,0859451,015849
    Operating Expenses Qtr Cr 761699758672738704
    Operating Profit Qtr Cr 316227327274277145
    Depreciation Qtr Cr 333333333232
    Interest Qtr Cr 112211
    Tax Qtr Cr 756385786331
    Net Profit Qtr Cr 236163220212212117
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 4,0883,544
    Operating Expenses Annual Cr 2,8522,712
    Operating Profit Annual in Cr 1,119699
    Depreciation Cr 132127
    Interest Annual Cr 75
    Tax Annual Cr 290141
    Net Profit Annual Cr 807559
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 735736
    Cash from Investing Activity Annual Cr 105-501
    Cash from Financing Annual Activity Cr -1,048-105
    Net Cash Flow Annual Cr -207130
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 3,4143,246
    Fixed Assets Annual Cr 1,7211,693
    Total Non Current Assets Annual Cr 1,7761,754
    Total Current Assets Annual Cr 2,4422,551
    Total Assets Annual Cr 4,2174,305
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 270257
    ROE Annual % 2417
    ROCE Annual % 3121
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3124
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,1451,0541,1051,0281,021882
    Operating Expenses Qtr Cr 815776791738750732
    Operating Profit Qtr Cr 330278314291271149
    Depreciation Qtr Cr 343434343333
    Interest Qtr Cr 122211
    Tax Qtr Cr 767581816130
    Net Profit Qtr Cr 246203210195208122
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 4,2933,841
    Operating Expenses Annual Cr 3,0372,959
    Operating Profit Annual in Cr 1,172783
    Depreciation Cr 135131
    Interest Annual Cr 76
    Tax Annual Cr 298157
    Net Profit Annual Cr 816588
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 785792
    Cash from Investing Activity Annual Cr 65-560
    Cash from Financing Annual Activity Cr -1,051-108
    Net Cash Flow Annual Cr -201124
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 3,5673,388
    Fixed Assets Annual Cr 1,7361,706
    Total Non Current Assets Annual Cr 1,9071,845
    Total Current Assets Annual Cr 2,7312,834
    Total Assets Annual Cr 4,6384,679
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 282268
    ROE Annual % 2317
    ROCE Annual % 3021
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3024
    Invest in Ajanta Pharma

    Ajanta Pharma Technicals

    EMA & SMA

    Current Price
    ₹3,350.35
    + 20.25 (0.61%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹3,086.58
    • 50 Day
    • ₹2,822.52
    • 100 Day
    • ₹2,597.05
    • 200 Day
    • ₹2,342.51
    • 20 Day
    • ₹3,109.88
    • 50 Day
    • ₹2,697.51
    • 100 Day
    • ₹2,510.14
    • 200 Day
    • ₹2,305.88

    Ajanta Pharma Resistance and Support

    PIVOT
    ₹3,350.6
    Resistance
    First Resistance 3,409.15
    Second Resistance 3,467.95
    Third Resistance 3,526.50
    RSI 71.89
    MFI 84.01
    MACD Single Line 153.47
    MACD 158.36
    Support
    First Support 3,291.80
    Second Support 3,233.25
    Third Supoort 3,174.45

    Ajanta Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 262,921 12,741,152 48.46
    Week 192,476 8,875,087 46.11
    1 Month 253,699 10,622,381 41.87
    6 Month 182,385 8,404,315 46.08

    Ajanta Pharma Result Highlights

    Ajanta Pharma Synopsis

    NSE-Medical-Generic Drugs

    Ajanta Pharma Lt is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 3971.12 Cr. and Equity Capital is Rs. 25.27 Cr. for the Year ended 31/03/2024. Ajanta Pharma Ltd. is a Public Limited Listed company incorporated on 31/12/1979 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1979PLC022059 and registration number is 022059.
    Market Cap 41,850
    Sales 4,034
    Shares in Float 4.25
    No of funds 290
    Yield 1.07
    Book Value 12.4
    U/D Vol ratio 2.7
    LTDebt / Equity
    Alpha 0.25
    Beta 0.27

    Ajanta Pharma Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 66.27%66.21%66.21%66.21%
    Mutual Funds 14.84%14.76%13.86%12.84%
    Insurance Companies 2.2%2.16%2.15%2.07%
    Foreign Portfolio Investors 8.36%8.54%9.11%9.99%
    Financial Institutions/ Banks
    Individual Investors 7.08%6.91%7.07%7.21%
    Others 1.25%1.42%1.6%1.68%

    Ajanta Pharma Management

    Name Designation
    Mr. Mannalal B Agrawal Chairman
    Mr. Madhusudan B Agrawal Vice Chairman
    Mr. Yogesh M Agrawal Managing Director
    Mr. Rajesh M Agrawal Joint Managing Director
    Mr. K H Viswanathan Independent Director
    Mr. Prabhakar R Dalal Independent Director
    Dr. Anjana Grewal Independent Director
    Mr. Chandrakant M Khetan Independent Director

    Ajanta Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Ajanta Pharma Corporate Action

    Date Purpose Remarks
    2024-07-30 Quarterly Results
    2024-05-02 Audited Results & Buy Back of Shares
    2024-01-31 Quarterly Results & 2nd Interim Dividend
    2023-10-31 Quarterly Results
    2023-07-27 Quarterly Results
    Date Purpose Remarks
    2024-02-08 INTERIM Rs.26.00 per share(1300%)Second Interim Dividend
    2023-08-04 SPECIAL Rs.15.00 per share(750%)Special Dividend
    2023-08-04 INTERIM Rs.10.00 per share(500%)First Interim Dividend
    2022-11-14 INTERIM Rs.7.00 per share(350%)Interim Dividend
    2021-11-10 INTERIM Rs.9.50 per share(475%)Interim Dividend
    Date Purpose Remarks
    2022-06-23 Bonus Rs.0.00 issue in the ratio of 1:2 of Rs. 2/-.

    Ajanta Pharma MF Shareholding

    Name Amount(cr)
    Nippon India Small Cap Fund - Growth 60,373
    Nippon India Multi Cap Fund - Growth 38,115
    Nippon India Growth Fund - Growth 33,707
    Axis Midcap Fund Growth 30,855
    UTI Flexi Cap Fund Regular Plan Growth 27,053

    Ajanta Pharma FAQs

    What is Share Price of Ajanta Pharma ?

    Ajanta Pharma share price is ₹3,350 As on 08 September, 2024 | 07:02

    What is the Market Cap of Ajanta Pharma ?

    The Market Cap of Ajanta Pharma is ₹41849.9 Cr As on 08 September, 2024 | 07:02

    What is the P/E ratio of Ajanta Pharma ?

    The P/E ratio of Ajanta Pharma is 49 As on 08 September, 2024 | 07:02

    What is the PB ratio of Ajanta Pharma ?

    The PB ratio of Ajanta Pharma is 11.8 As on 08 September, 2024 | 07:02

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of ₹10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.